Kenvue shares rose 6% on Tuesday, September 23, 2025, after falling to a record low the previous session. The rebound followed President Donald Trump’s remarks linking Tylenol’s active ingredient, acetaminophen, to autism and a September 22 announcement that the FDA was beginning a label-change process. Reuters reported that investors had braced for a major announcement, but the White House event presented no new scientific evidence supporting the claim. This was a two-session market reaction—not proof about the medical evidence, Kenvue’s long-term prospects, or its current share price.
What happened to Kenvue shares?
The move unfolded over two separate trading sessions. The Associated Press reported that Kenvue shares fell 7.5% on Monday, September 22, 2025, reducing the company’s market value by about $2.6 billion. Reuters reported that shares climbed 6% the next day, rebounding from the prior session’s record low.
| Date | Reported move | Source and context |
|---|---|---|
| September 22, 2025 | Shares fell 7.5%; market value declined by about $2.6 billion. | Associated Press report on that day’s trading: AP. |
| September 23, 2025 | Shares rose 6%, rebounding from a record low in the previous session. | Reuters report published that day: Reuters, republished by Investing.com. |
Those are historical figures reported for individual sessions, not current stock data. They should not be combined into a precise two-day return: the reports give rounded daily moves and do not establish a calculated cumulative return.
Why did the shares rebound?
Reuters attributed the rebound in part to investors’ reaction to the lack of a major new announcement or new scientific evidence at the White House event. The prospect of a high-profile announcement had weighed on expectations; after the event, investors had less reason to price in an immediate, newly substantiated development. That is a market interpretation of a short-term move, not a demonstrated explanation for every trade or a judgment about Kenvue’s future performance.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
Reuters quoted James Harlow, vice president at Novare Capital Management, describing the mood: “Investors were holding their breath worried that yesterday’s announcement would be a bombshell. It turned out it wasn’t, as no new scientific evidence was presented linking Tylenol to autism,” The remark is market commentary about what investors expected and heard; it is not a scientific finding.
What was announced on September 22?
Trump’s public remarks
Trump publicly linked Tylenol and acetaminophen use during pregnancy to autism. The claim was part of a broader set of autism-related announcements. A public assertion, however, is distinct from what regulators said about the evidence.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
The FDA’s label-change process
On September 22, 2025, the FDA said it had initiated a process to change labeling for acetaminophen products, including Tylenol and similar medicines, and had alerted physicians. The agency said some studies had reported an association between use during pregnancy and later autism or ADHD diagnoses, while emphasizing that causation had not been established and that contrary studies existed. The FDA release described findings from large cohort studies, including the Nurses’ Health Study II and Boston Birth Cohort; it did not give a pooled effect size. FDA Commissioner Marty Makary said the agency was acting “to make parents and doctors aware of a considerable body of evidence about potential risks associated with acetaminophen.” Read the FDA’s September 22 statement.
HHS’s broader statement
The Department of Health and Human Services also described the evidence as conflicting and said clear causal evidence was lacking. Its statement acknowledged that untreated fever during pregnancy can pose risks and said clinicians should use judgment. When treatment is required, HHS advised using the lowest effective dose for the shortest duration. The statement did not establish that acetaminophen causes autism. Read the HHS announcement.
What the agency statements do—and do not—establish
The FDA and HHS statements support careful wording: some studies reported an association, but the agencies did not say that a causal relationship had been proven. An association in a study does not by itself establish that a medicine caused an outcome. The FDA also noted contrary studies, and HHS characterized the literature as conflicting.
The FDA said it remained reasonable for pregnant women to use acetaminophen in certain scenarios. The agency statements cited here describe what FDA and HHS said on September 22, 2025; they do not establish the present status of the labeling process or the current product label. They are not individualized medical advice. Anyone making a treatment decision during pregnancy should consult a clinician.
Rank #4
What the rebound means for investors
The September 23 rise indicates that Kenvue shares recovered part of a sharp preceding-session decline; it does not show that the company’s business outlook changed, that the medical debate was resolved, or that the stock was fairly valued. Nor does the reported 6% increase tell a reader what the shares trade for now. A short-term share move can reflect shifting expectations and uncertainty, not a lasting reassessment of a company.
For a personal-finance decision, treat the reported percentages and market-value estimate as dated news from September 2025—not as current quotes, forecasts, or a buy-or-sell recommendation. The available reports do not establish a present-day Kenvue price or investment outlook.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
